Cargando…
Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern
In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69–70 + N501Y + E gene triplexes (one opti...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134755/ https://www.ncbi.nlm.nih.gov/pubmed/35644262 http://dx.doi.org/10.1016/j.jviromet.2022.114553 |
_version_ | 1784713825015037952 |
---|---|
author | Pabbaraju, Kanti Zelyas, Nathan Wong, Anita Croxen, Matthew A. Lynch, Tarah Buss, Emily Murphy, Stephanie Shokoples, Sandy Kanji, Jamil Tipples, Graham |
author_facet | Pabbaraju, Kanti Zelyas, Nathan Wong, Anita Croxen, Matthew A. Lynch, Tarah Buss, Emily Murphy, Stephanie Shokoples, Sandy Kanji, Jamil Tipples, Graham |
author_sort | Pabbaraju, Kanti |
collection | PubMed |
description | In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69–70 + N501Y + E gene triplexes (one optimized for Alpha [B.1.1.7] and one optimized for Omicron [B.1.1.529]), a K417N + 242–244 wild-type duplex, a K417T + E484K duplex, and a L452R + P681 + E484Q triplex. Depending on the assay, sensitivity was 98.97–100% for the detection of known VOC-positive samples, specificity was 97.2–100%, limit of detection was 2–116 copies/reaction, intra- and interassay variability was less than 5%, and no cross-reactivity with common respiratory pathogens was observed with any assay. A subset of rRT-PCR- positive VOC samples were further characterized by genome sequencing. A comparison of the lineage designation by the VOC rRT-PCR assays and genome sequencing for the detection of the Alpha, Beta, Gamma, Delta and Omicron variants showed clinical sensitivities of 99.97–100 %, clinical specificities of 99.6–100 %, positive predictive values of 99.8–100%, and negative predictive values of 99.98–100 %. We have implemented these rRT-PCR assays targeting discriminatory single nucleotide polymorphisms for ongoing VOC screening of SARS-CoV-2 positive samples for surveillance purposes. This has proven extremely useful in providing close to real-time molecular surveillance to monitor the emergence of Alpha, the replacement of Alpha by Delta, and the replacement of Delta by Omicron. While the design, validation and implementation of the variant specific PCR targets is an ever-evolving approach, we find the turn-around-time, high throughput and sensitivity to be a useful complementary approach for SARS-CoV-2 genome sequencing for surveillance purposes in the province of Alberta, Canada. |
format | Online Article Text |
id | pubmed-9134755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91347552022-05-26 Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern Pabbaraju, Kanti Zelyas, Nathan Wong, Anita Croxen, Matthew A. Lynch, Tarah Buss, Emily Murphy, Stephanie Shokoples, Sandy Kanji, Jamil Tipples, Graham J Virol Methods Article In order to detect the SARS-CoV-2 variants of concern (VOCs), five real-time reverse transcriptase PCR (rRT-PCR) assays were designed to target the critical discriminatory mutations responsible for the following amino acid changes in the spike protein: two Δ69–70 + N501Y + E gene triplexes (one optimized for Alpha [B.1.1.7] and one optimized for Omicron [B.1.1.529]), a K417N + 242–244 wild-type duplex, a K417T + E484K duplex, and a L452R + P681 + E484Q triplex. Depending on the assay, sensitivity was 98.97–100% for the detection of known VOC-positive samples, specificity was 97.2–100%, limit of detection was 2–116 copies/reaction, intra- and interassay variability was less than 5%, and no cross-reactivity with common respiratory pathogens was observed with any assay. A subset of rRT-PCR- positive VOC samples were further characterized by genome sequencing. A comparison of the lineage designation by the VOC rRT-PCR assays and genome sequencing for the detection of the Alpha, Beta, Gamma, Delta and Omicron variants showed clinical sensitivities of 99.97–100 %, clinical specificities of 99.6–100 %, positive predictive values of 99.8–100%, and negative predictive values of 99.98–100 %. We have implemented these rRT-PCR assays targeting discriminatory single nucleotide polymorphisms for ongoing VOC screening of SARS-CoV-2 positive samples for surveillance purposes. This has proven extremely useful in providing close to real-time molecular surveillance to monitor the emergence of Alpha, the replacement of Alpha by Delta, and the replacement of Delta by Omicron. While the design, validation and implementation of the variant specific PCR targets is an ever-evolving approach, we find the turn-around-time, high throughput and sensitivity to be a useful complementary approach for SARS-CoV-2 genome sequencing for surveillance purposes in the province of Alberta, Canada. Published by Elsevier B.V. 2022-09 2022-05-26 /pmc/articles/PMC9134755/ /pubmed/35644262 http://dx.doi.org/10.1016/j.jviromet.2022.114553 Text en © 2022 Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Pabbaraju, Kanti Zelyas, Nathan Wong, Anita Croxen, Matthew A. Lynch, Tarah Buss, Emily Murphy, Stephanie Shokoples, Sandy Kanji, Jamil Tipples, Graham Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern |
title | Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern |
title_full | Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern |
title_fullStr | Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern |
title_full_unstemmed | Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern |
title_short | Evolving strategy for an evolving virus: Development of real-time PCR assays for detecting all SARS-CoV-2 variants of concern |
title_sort | evolving strategy for an evolving virus: development of real-time pcr assays for detecting all sars-cov-2 variants of concern |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134755/ https://www.ncbi.nlm.nih.gov/pubmed/35644262 http://dx.doi.org/10.1016/j.jviromet.2022.114553 |
work_keys_str_mv | AT pabbarajukanti evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT zelyasnathan evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT wonganita evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT croxenmatthewa evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT lynchtarah evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT bussemily evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT murphystephanie evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT shokoplessandy evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT kanjijamil evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern AT tipplesgraham evolvingstrategyforanevolvingvirusdevelopmentofrealtimepcrassaysfordetectingallsarscov2variantsofconcern |